CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings
Wednesday, May 5, 2021 6:55PM IST (1:25PM GMT)
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
San Diego, United States:
Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research organization located in the Netherlands. Through the acquisition, CrownBio will expand its portfolio of
in vitro services, integrating OcellO’s expertise in high content imaging alongside CrownBio’s
Home / Top News / Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
AC – Inflammation was Mild and Decreasing over Time in Cohort 3
AC – Inflammation was Mild and Decreasing over Time in Cohort 3
VC – Inflammation was Mild and Decreasing over Time in Cohort 3
VC – Inflammation was Mild and Decreasing over Time in Cohort 3
Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3
Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3
Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
Urges Stockholders to Vote the
WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.
REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has filed a new investor presentation with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Stockholders (“Annual Meeting”). The presentation is available at https://investors.adverum.com/shareholder-services/annual-meeting.
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.